Cerep selected by the SGC as a preferred CRO to provide screening and profiling services on epigenetic targets
Paris, France, June 7, 2011 – press release 2011/01
The Structural Genomic Consortium (SGC) and Cerep today announced that Cerep has been selected by the SGC as the worldwide-preferred provider of screening and profiling services for the discovery of small molecule chemical probes and drug candidates on epigenetic targets.
Epigenetic targets are proteins that regulate gene expression without changing the DNA sequence. In recent years, epigenetics has developed into one of the most dynamic areas of biological research with an increasing number of drug discovery programs in cancer, inflammation, metabolic and neuro- psychiatric diseases. Cerep anticipates drug screening on these targets to increase significantly in coming years. The number of human epigenetic targets is over 500. Already the SGC has purified more than 250 of them and has developed assays for over a hundred.
Under the terms of the agreement, the SGC and Cerep will collaborate to produce epigenetic proteins and to develop and publish assays suitable for rapid and robust high throughput screening and profiling of compounds on these targets. Cerep will offer these services to the entire community of scientists in the public and private sectors from its laboratories, including a new lab to be built in Toronto.
Thierry Jean, CEO of Cerep declared: « We are very happy and proud to have been selected by such a renowned organisation as the SGC and by its pharma partners. We are delighted to be given, through
Code ISIN FR0004042232
Alternext Paris this collaboration, the opportunity to expand our offer to include families of epigenetic targets. A signifi- cant part of our R&D budget in 2011 and 2012 will be dedicated to the development of new assays for
Cerep SA
Le Bois l’Evêque epigenetic targets, in partnership with the SGC. Our goal is to become the preferred provider of ser- 86600 Celle l’Evescault France vices in this field further solidifying our position as the leader in screening and profiling services. We tél : +33 (0)5 49 89 30 00 fincom@cerep.fr are confident our partners will strongly benefit from the quality of our new panel in epigenetics. » www.cerep.com
.
Aled Edwards, CEO of the SGC looks ahead: « I am so excited about our partnership with Cerep, a
Statements included in this press company that is held in such high regard in the sector. This open access collaboration will allow us to release which are not historical in nature are intended to be, and transfer our scientific advances into the hands of scientists around the world as quickly as possible. » are hereby identified as, « forward- looking statements » for purposes of the safe harbor provided by Section 21E of the Securities Exchange Act of 1934, as amended by the Private
Contacts
Securities Litigation Reform Act of 1995. Forward-looking statements
Thierry Jean, Chairman & CEO Aled Edwards, CEO may be identified by words including « anticipates », « believes »,
Cerep The Structural Genomics Consortium
« intends », « estimates », « expects » and similar expressions. The company
Tel. +33 (0)5 49 89 30 00 Tel. +1 416 3578 724 cautions readers that forward- looking statements, including fincom@cerep.fr aled.edwards@utoronto.ca without limitation those relating to the company’s future operations and business prospects, are subject to certain risks and uncertainties
About Cerep that could cause actual results to differ materially from those indicated
Focussing on in vitro pharmacology and ADME-Tox, Cerep provides solutions allowing cost- in the forward-looking statements.
Factors that may affect future effective drug discovery by identifying at early stages the most promising drug candidates and operations and business prospects include, but are not limited to, eliminating compounds likely to fail in development. Cerep’s technologies benefit to about 500 scientific results and developments concerning corporate collaborations pharmaceutical and biotechnological companies worldwide including most of the top pharmaceu- and the company’s proprietary rights and other factors described in tical firms. the company’s Annual Report.

Télécharger le communiqué
!:!iframe http://www.nextnews.fr/upload/fr/nextnews%5Fcerep%5Fcerep%5Fselected%5Fby%5Fthe%5Fsgc%5Fas%5Fa%5Fpreferred%5Fcro%5Fto%5Fprovide%5Fscreening%5Fand%5Fprofiling%5Fservices%5Fon%5Fepigenetic%5Ftargets%5F55808%2EPDF!:!

En partenariat avec NextNews

Tags: Communiqués entreprises, entreprises